Business Context and Reporting Period
Contineum Therapeutics, Inc. (CTNM), a Delaware corporation, filed this Form 8-K on March 5, 2026. The filing primarily reports the announcement of financial results for the fourth quarter ended December 31, 2025, and details an amendment to an existing equity sales agreement.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the specific financial results for the fourth quarter of 2025. However, the text of this 8-K does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these figures.
Material Changes and Corporate Actions
- ATM Program Expansion: The Company amended its Sales Agreement with Leerink Partners LLC to increase the aggregate offering price of Class A common stock available for sale from $75,000,000 to $100,000,000.
- Prospectus Update: A new prospectus supplement was filed on March 5, 2026, superseding the prior supplement dated May 23, 2025.
- Sales Restriction: The Company agreed not to sell any shares under the amended agreement until March 11, 2026, coinciding with the expiration of a lock-up period from a December 11, 2025, underwriting agreement.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on future performance, or a discussion of risks beyond standard legal disclaimers regarding the securities offering. The Company is not obligated to sell any shares under the amended agreement.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 2025 financial metrics (revenue, net loss, cash position).
- Confirm the remaining unsold capacity under the original $75 million agreement to calculate the total new equity available.
- Monitor share sales activity post-March 11, 2026, to assess potential dilution from the new $100 million ATM program.
- Verify the terms of the December 11, 2025, underwriting agreement referenced in the lock-up period.